



Date: December 16, 2019
To: All Zones
From: Alberta Precision Laboratories (APL) – North Sector, University of Alberta Hospital
Re: New Maternal Prenatal Screen Requisition

PLEASE POST OR DISTRIBUTE AS WIDELY AS APPROPRIATE

Key Message:

- Effective immediately a revised Maternal Prenatal Screen requisition is available for use.

Why this is important:

- This requisition aligns with SOGC clinical practice guidelines and reflects new data requirements for a prenatal software upgrade including:
 - Indications for Second Trimester AFP for open neural tube defect screening (MOMA)
 - Targeted questions regarding medications
- The new requisition must be used and the new fields completed to ensure accurate risk assessment for neural tube defects and to avoid delays in patient testing and reporting.
- If MOMA is ordered and no clinical indication is provided, the test will be cancelled.

Action Required:

- Discard outdated copies of the Maternal Prenatal Screen Requisition (First and Second Trimester)
- The revised Maternal Prenatal Screen Requisition can be obtained from the APL or DynaLIFE websites or at <https://www.albertahealthservices.ca/frm-CH-1247.pdf>

North and Edmonton Zones:

- The Maternal Prenatal Screen requisition should be used to order the following tests: First Trimester Prenatal Screen (FTPS), Second Trimester Maternal Serum Quad Screen (MOM), and Second Trimester AFP for open neural tube defect screening (MOMA).

Central Zone:

- The Maternal Prenatal Screen requisition should be used to order the following tests: First Trimester Prenatal Screen (FTPS), Second Trimester Maternal Serum Quad Screen (MOM), and Second Trimester AFP for open neural tube defect screening (MOMA) *if the sample is being shipped to Edmonton for testing.*

South Zone:

- The Maternal Prenatal Screen requisition should be used to order Second Trimester Maternal Serum Quad Screen (MOM) and Second Trimester AFP for open neural tube defect screening (MOMA).

Inquiries and feedback may be directed to:

- Genetic Counsellors, University of Alberta Hospital, 780-407-7907

This bulletin has been reviewed and approved by:

- Dr. Kareena Schnabl, Interim Section Chief Clinical Biochemistry – APL North Sector
- Dr. Michael Mengel, Medical Director – APL North Sector
- Dr. Hossein Sadrzadeh, Clinical Biochemistry Section Chief – APL South